Showing 4111-4120 of 6036 results for "".
- Lumibird Unveils Omnicad Imaging Platform for Ocular Surface Diseasehttps://modernod.com/news/lumibird-unveils-omnicad-imaging-platform-for-ocular-surface-disease/2482453/Lumibird Medical announced the launch of the Omnicad, an imaging platform equipped with integrated AI algorithms designed to aid in the diagnosis of ocular surface disease (OSD). The device, exclusively available in the US market, aims to address the needs of optometrists and ophthalmol
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- iCare Launches ST500 Slit-Lamp Based Tonometerhttps://modernod.com/news/icare-launches-st500-slit-lamp-based-tonometry/2482436/iCare announced the release of the iCare ST500, a slit-lamp-based tonometer that brings the features of iCare’s rebound tonometry technology into a modern design. The iCare ST500 offers an advanced solution for IOP measurement, combining extreme ease of u
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Atsena Therapeutics Publishes 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in LCA1https://modernod.com/news/atsena-therapeutics-publishes-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-lca1/2482431/Atsena Therapeutics announced 12-month safety and efficacy results from its phase 1/2 clinical trial of ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA1), a rare inherited retinal disease causing severe vision impairment or blindness from infancy. The findi
- Alcon Announces New Cataract Surgery Outcomes Data, Hosts Educational Program at ESCRShttps://modernod.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/Alcon is set to unveil new scientific data at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, from September 6-10, 2024. The company will showcase its surgical ophthalmic products and equipment, highlighting innovations designed to optimize
- Oculus Unveils Pentacam Cornea OCThttps://modernod.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/Oculus is introducing the Pentacam Cornea OCT, a tool that combines Scheimpflug technology with the world’s first pericentric OCT scanning system, according to a company news release. The device provides cornea specialists with imaging capabilities, capturing both Scheimpflug
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Haag-Streit Introduces METIS Ophthalmic Microscope Systemhttps://modernod.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/Haag-Streit has introduced the METIS ophthalmic microscope system, which is designed to provide optical performance, ergonomic design, and advanced features tailored for precision and efficiency. Superior Optical Experience The METIS microscope integrates Haag